IRVINE, Calif., April 10, 2012 /PRNewswire/ -- GeneTex, a leading manufacturer of antibodies, is pleased to announce that they will be launching a new antibody against CAIX, a marker of hypoxia that shows great promise for cancer research.
Hypoxia in tumors is closely associated with tumor aggressiveness and resistance to radio- and chemotherapeutic treatment. Therefore, reliable markers for hypoxia represent both valuable diagnostic markers and potential targets for therapeutic intervention.
Carbonic anhydrase IX, or CAIX, is a transmembrane protein whose expression is restricted to very few normal tissues, in particular the membranes of gastric mucosal epithelial cells. Under hypoxic conditions, hypoxia inducible factor-1 alpha (HIF-1a) is stabilized and the transcription factor HIF-1 transactivates the CA9 gene, resulting in expression of the CAIX protein in the hypoxic cells. CAIX is involved in both the extracellular acidification of hypoxic tumors, as well as the regulation of intracellular pH, making it an attractive target for therapies based on the manipulation of pH (Parks, et al., 2010).
CAIX is considered to be one of the best cellular biomarkers of hypoxia. Furthermore, recent studies examining the association between CAIX levels and various clinicopathological outcomes suggest that CAIX expression may also be a valuable prognostic indicator for overall survival (Kirkpatrick et al., 2008; Jubb et al., 2009).
GeneTex is proud to introduce a superior monoclonal antibody against CAIX that has been fully validated through immunohistochemistry, immunofluorescence, western blotting and FACS.
For additional information on GeneTex's hypoxia antibodies, call toll-free 877-GENETEX (436-3839) or visit www.GeneTex.com/hypoxia.
GeneTex is an antibody company that was founded by scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation. GeneTex has over 55,000 primary antibodies in its catalog that are all backed by a 100% Satisfaction Guarantee.
Jubb AM, Buffa FM, Harris AL. Assessment of Tumour Hypoxia for Prediction of Response to Therapy and Cancer Prognosis. J Cell Mol Med. 2009 Jan 14(1-2):18-29.